Biocon ranked among top five biotech employers globally

October 30, 2020 08:43 pm | Updated 08:43 pm IST - Bengaluru

Biocon Ltd, a Bengaluru-headquartered biopharmaceuticals company, has been ranked among the Top 5 Global Biotech Employers for 2020 in the U.S.-based Science magazine’s annual‘Science Careers Top 20 Employers’ list, a statement from Biocon said.

The other top pharma employers in the list are Regeneron, Alnylam, Incyte and Syngenta.

With this ranking, Biocon has moved up from No. 7 in 2018 and No. 6 in 2019 and to No.5 this year, ahead of global pharma companies like Novo Nordisk, Roche, Eli Lilly,Abbott, Novartis, Pfizer etc.

The company has consistently among the top global employers for eight consecutive years, since its debut on the list in 2012.

According to the Top Employers Survey of approximately 7,600 respondents from across the world this year, Biocon’s ranking was based on three key attributes: ‘innovative leader in the industry,’ ‘is socially responsible’ and ‘has loyal employees,’ the statement added.

This year, the survey was held from March 3 through May 3, when companies globally a were grappling with quarantines and lockdowns in response to COVID-19.

Biocon executive chairperson Kiran Mazumdar-Shaw said, “We are delighted to be ranked among the Top Five Global Biotech Employers by Science Magazine. The ranking is a recognition of the passion that our employees bring to the job, which allowed us to run essential and critical manufacturing, quality and supply operations with reduced staffing despite the severe disruptions caused by the COVID-19 outbreak, thus minimising the impact on patients and partners. Their commitment also enabled us to rapidly develop novel therapeutics for the deadly coronavirus and serve humanity by fighting COVID-19.”

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.